{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Vanflyta"},{"type":"CodeName","name":"AC220 2HCl"},{"type":"Synonym","name":"N-(5-tert-butyl-isoxazol-3-yl)-N'-(4-(7-(2-morpholin-4-ylethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea dihydrochloride"},{"type":"Synonym","name":"AC010220 2HCl"},{"type":"CASRegistryName","name":"1132827-21-4"},{"type":"ChemicalStructureName","name":"urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N'-(4-(7-(2-(4-morpholinyl) ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)-, hydrochloride (1:2)"}],"definition":{"html":"The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","text":"The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/quizartinib-dihydrochloride","text":"Quizartinib Dihydrochloride"},"nciConceptId":"C97272","nciConceptName":"Quizartinib Dihydrochloride","termId":547019,"name":"quizartinib dihydrochloride","firstLetter":"q","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"quizartinib-dihydrochloride"}],"links":null}